Allianz Asset Management’s Aerie Pharmaceuticals AERI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q4 | – | Sell |
-24,100
| Closed | -$365K | – | 2063 |
|
|
2022
Q3 | $365K | Sell |
24,100
-145,275
| -86% | -$1.69M | ﹤0.01% | 1573 |
|
|
2022
Q2 | $1.27M | Buy |
169,375
+15,170
| +10% | +$107K | ﹤0.01% | 1587 |
|
|
2022
Q1 | $1.4M | Buy |
154,205
+45,380
| +42% | +$350K | ﹤0.01% | 1729 |
|
|
2021
Q4 | $764K | Sell |
108,825
-27,400
| -20% | -$287K | ﹤0.01% | 2019 |
|
|
2021
Q3 | $1.55M | Hold |
136,225
| – | – | ﹤0.01% | 1746 |
|
|
2021
Q2 | $2.18M | Sell |
136,225
-16,355
| -11% | -$281K | ﹤0.01% | 1444 |
|
|
2021
Q1 | $2.73M | Hold |
152,580
| – | – | ﹤0.01% | 1288 |
|
|
2020
Q4 | $2.06M | Hold |
152,580
| – | – | ﹤0.01% | 1305 |
|
|
2020
Q3 | $1.79M | Buy |
152,580
+10,950
| +8% | +$133K | ﹤0.01% | 1296 |
|
|
2020
Q2 | $2.09M | Buy |
141,630
+71,375
| +102% | +$1.06M | ﹤0.01% | 1589 |
|
|
2020
Q1 | $948K | Buy |
70,255
+25,134
| +56% | +$477K | ﹤0.01% | 1818 |
|
|
2019
Q4 | $1.09M | Buy |
45,121
+1,473
| +3% | +$30.5K | ﹤0.01% | 2146 |
|
|
2019
Q3 | $853K | Sell |
43,648
-1,090
| -2% | -$25K | ﹤0.01% | 2187 |
|
|
2019
Q2 | $1.32M | Sell |
44,738
-16,747
| -27% | -$645K | ﹤0.01% | 2042 |
|
|
2019
Q1 | $2.92M | Buy |
61,485
+18,127
| +42% | +$798K | ﹤0.01% | 1690 |
|
|
2018
Q4 | $1.56M | Buy |
+43,358
| New | +$2.03M | ﹤0.01% | 1851 |
|
Allianz Asset Management's AERI Position: Q4 2022 in Review
Allianz Asset Management sold out of Aerie Pharmaceuticals (AERI) in Q4 2022, closing a stake of 24,100 shares — an estimated $365K sold.
Allianz Asset Management first reported a position in AERI in Q4 2018 and held it in 16 quarters. The position peaked at $2.92M in Q1 2019. 0 funds tracked by Wall St. Rank hold AERI as of Q4 2022.
- Allianz Asset Management reported no remaining Aerie Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
- Allianz Asset Management sold 24,100 Aerie Pharmaceuticals shares in Q4 2022, an estimated $365K.
- Allianz Asset Management first reported a position in Aerie Pharmaceuticals in Q4 2018 and held it in 16 quarters.
- Allianz Asset Management's Aerie Pharmaceuticals position peaked at $2.92M in Q1 2019.
- 0 funds tracked by Wall St. Rank held Aerie Pharmaceuticals as of Q4 2022.
Based on Allianz Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.